Quoin pharmaceuticals targeting regulatory approvals for lead candidate for netherton syndrome in 2024

As company (qnrx) gains strength, chief operating officer, denise carter, talks about what's next for quoinnew york, new york--(newsfile corp. - march 24, 2022) - pcg digital -- netherton syndrome (ns) is a rare and devastating skin disease that is estimated to affect between 2,000 and 4,000 people in the united states, and a similar number in europe. it has no cure, and current treatment primarily involves the use of over-the-counter moisturizers which provide only minor symptomatic relief.quoin pharmaceuticals' (nasdaq: qnrx) investigational product for ns, qrx003, may become the first...
QNRX Ratings Summary
QNRX Quant Ranking